{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:03:25Z","timestamp":1790114605783,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.trecan.2026.08.009","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:16:39Z","timestamp":1789992999000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation tumor-agnostic targets on the horizon"],"prefix":"10.1016","author":[{"given":"Niamh","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.08.009_bb0005","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.trecan.2026.08.009_bb0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"Campbell","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.009_bb0020","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1200\/JCO.2020.38.15_suppl.109","article-title":"Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0050","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0055","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAF V600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0060","article-title":"Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors","volume":"43","author":"Gouda","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.trecan.2026.08.009_bb0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb2005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.trecan.2026.08.009_bb0135","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0140","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0070","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0075","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0080","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-025-60369-1","article-title":"Tissue-agnostic cancer therapies: promise, reality, and the path forward","volume":"16","author":"Subbiah","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.009_bb0085","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.009_bb0090","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0100","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2022.40.16_suppl.2587","article-title":"Efficacy and safety of dostarlimab in patients with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study","volume":"40","author":"Andr\u00e9","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0110","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0115","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0120","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.08.009_bb0125","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100079","article-title":"Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study","volume":"6","author":"Cascone","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.trecan.2026.08.009_bb0145","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2026.08.009_bb0150","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/1078-0432.CCR-18-2062","article-title":"Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer","volume":"25","author":"Dagogo-jack","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0155","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0160","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAF V600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0170","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAF V600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0180","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0185","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging all KRAS mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0190","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0195","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0200","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS G12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509","article-title":"KRYSTAL-12: phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0215","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0220","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KRAS G12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0225","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT019","article-title":"Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors","volume":"85","author":"Arbour","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0230","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2025.43.4_suppl.724","volume":"43","author":"Spira","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0235","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1538-7445.AM2025-1662","article-title":"Preclinical studies of RP04340: an orally available and potent PROTAC compound targeting KRAS G12C\/D\/V mutant tumors","volume":"85","author":"Ji","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0240","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1158\/1538-7445.AM2025-397","article-title":"Combinatorial use of VHL and KEAP1-based PROTACs reveals unexpected synergy and hook effect relief","volume":"85","author":"Islam","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0245","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ccell.2025.05.006","article-title":"Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy","volume":"43","author":"Benton","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.08.009_bb0250","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1200\/EDBK_325885","article-title":"Taking aim at the undruggable","volume":"41","author":"Coleman","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.trecan.2026.08.009_bb0255","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2026.08.009_bb0260","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0265","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1\u2013FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114585","article-title":"58 (PB046): tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients with advanced solid tumors with FGFR2 fusions or rearrangements: the ReFocus study","volume":"211","author":"Hollebecque","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.08.009_bb0275","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2023.12.004","article-title":"Targeting HER2-mutant metastatic cervical cancer with neratinib: final results from the phase 2 SUMMIT basket trial","volume":"181","author":"Friedman","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0280","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/2159-8290.CD-21-0226","article-title":"Targeting EGFR exon 20 insertions in non-small cell lung cancer: recent advances and clinical updates","volume":"11","author":"Meador","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0285","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3187","article-title":"Beamion PANTUMOR-1: a phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2-mutated or overexpressed\/amplified solid tumors","volume":"43","author":"Schram","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0295","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of Afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0300","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0305","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1200\/JCO.2022.40.16_suppl.3006","article-title":"CRESTONE: initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions","volume":"40","author":"Carrizosa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0310","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2026.08.009_bb0315","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.08.009_bb0320","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/JCO.2022.40.4_suppl.604","article-title":"Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss)","volume":"40","author":"Ngoi","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0325","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/1538-7445.AM2025-1122","article-title":"Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data","volume":"85","author":"Ikushima","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0330","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/his.15502","article-title":"Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma","volume":"87","author":"Quaranta","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.trecan.2026.08.009_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100420","article-title":"Comparison of immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization for detection of MTAP loss in pleural mesothelioma","volume":"37","author":"Febres-Aldana","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0340","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-022-00348-3","article-title":"Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome","volume":"3","author":"Golbourn","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.trecan.2026.08.009_bb0345","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0350","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0355","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0360","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.ejca.2024.114979","article-title":"Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted (del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)","volume":"211","author":"Herzberg","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2026.08.009_bb0365","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.semcancer.2020.07.005","article-title":"Targeting p53 for the treatment of cancer","volume":"79","author":"Duffy","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0370","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1056\/NEJMoa2508820","article-title":"Phase 1 study of rezatapopt, a p53 reactivator, in TP53 Y220C-mutated tumors","volume":"394","author":"Dumbrava","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0375","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0380","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1038\/s41467-024-49932-4","article-title":"Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses","volume":"15","author":"Malli Cetinbas","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.08.009_bb0385","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0420","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2014.60.4165","article-title":"Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials","volume":"33","author":"Meric-Bernstam","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0425","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS214","article-title":"A phase 1b study of sotorasib, a specific and irreversible KRAS G12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)","volume":"40","author":"Hong","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0430","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.08.009_bb0435","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.trecan.2026.08.009_bb0445","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2026.08.009_bb0450","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0455","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1158\/0008-5472.CAN-14-0761","article-title":"Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs","volume":"74","author":"Pennacchietti","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.08.009_bb0460","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2026.08.009_bb0465","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1019111","article-title":"Spatial transcriptomics technology in cancer research","volume":"12","author":"Yu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2026.08.009_bb0475","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.cell.2025.12.049","article-title":"Hallmarks of cancer\u2014then and now, and beyond","volume":"189","author":"Hanahan","year":"2026","journal-title":"Cell"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326002050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:13:05Z","timestamp":1790111585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326002050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":90,"alternative-id":["S2405803326002050"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.08.009","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation tumor-agnostic targets on the horizon","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}